-
公开(公告)号：US20180364175A1
公开(公告)日：2018-12-20
申请号：US16111646
申请日：2018-08-24
Applicant: Roche Diagnostics Operations, Inc.
Inventor： Hans-Peter Josel , Herbert Andres , Michaela Windfuhr , Oliver Larbolette , Stefan Quint
Abstract: The disclosure concerns methods for the detection of an analyte in a sample by electrochemiluminescence using new reagent compositions. New reagent compositions, reagent kits for measuring electrochemiluminscence (ECL) and electrochemiluminescence detection methods using the new reagent compositions are disclosed. In particular, the disclosure relates to the use of novel combinations of compounds which can be used in said measurements to provide improved assay performance.
-
公开(公告)号：US20180003710A1
公开(公告)日：2018-01-04
申请号：US15673976
申请日：2017-08-10
Applicant: Roche Diagnostics Operations, Inc.
Inventor： Herbert Andres , Stefan Weiser , Johann Karl , Ursula Kunert , Florian Grupp
IPC: G01N33/564 , G01N33/563 , G01N33/58
CPC classification number: G01N33/564 , G01N33/563 , G01N33/58 , G01N2333/91215 , G01N2800/102
Abstract: The present invention relates to a method aiding in the assessment of rheumatoid arthritis (“RA”). The method is used in assessing RA in vitro. It is practiced by analyzing biochemical markers, comprising measuring the concentration of anti-CCP and anti-PIK3CD and correlating the concentrations determined to the absence or presence of RA. The invention also relates to the use of a marker panel comprising anti-CCP and anti-PIK3CD in the diagnosis of RA and it teaches a kit for performing the method of the invention. Further the invention relates to the use of a marker panel comprising anti-CCP and anti-PIK3CD to differentiate RA from other autoimmune diseases, preferably osteoarthritis (OA).
-
公开(公告)号：US20240272154A1
公开(公告)日：2024-08-15
申请号：US18616550
申请日：2024-03-26
Applicant: Roche Diagnostics Operations, Inc.
Inventor： Herbert Andres , Johann Karl , Ursula Kunert , David Morgenstern , Nina Meissler , Marion Niessner , Magdalena Swiatek-de Lange
IPC: G01N33/564 , C07K16/46 , G01N33/574
CPC classification number: G01N33/564 , C07K16/46 , G01N33/574 , G01N33/5748 , G01N33/57496
Abstract: An in vitro method is disclosed for detecting an antibody to p53 (anti-p53 antibody) in a sample, the method comprising: incubating a sample to be analyzed with a p53 capture antigen and a p53 detection antigen, whereby a complex comprising the p53 capture antigen, the anti-p53 antibody and the p53 detection antigen is formed, separating the complex formed from unbound detection antigen and measuring the complex obtained via the detection antigen comprised therein, thereby detecting the anti-p53 antibody comprised in the sample.
-
公开(公告)号：US11971407B2
公开(公告)日：2024-04-30
申请号：US17730403
申请日：2022-04-27
Applicant: Roche Diagnostics Operations, Inc.
Inventor： Herbert Andres , Johann Karl , Ursula Kunert , David Morgenstern , Nina Meissler , Marion Niessner , Magdalena Swiatek-de Lange
IPC: G01N33/53 , C07K16/46 , G01N33/564 , G01N33/574
CPC classification number: G01N33/564 , C07K16/46 , G01N33/574 , G01N33/5748 , G01N33/57496
Abstract: An in vitro method is disclosed for detecting an antibody to p53 (anti-p53 antibody) in a sample, the method comprising: incubating a sample to be analyzed with a p53 capture antigen and a p53 detection antigen, whereby a complex comprising the p53 capture antigen, the anti-p53 antibody and the p53 detection antigen is formed, separating the complex formed from unbound detection antigen and measuring the complex obtained via the detection antigen comprised therein, thereby detecting the anti-p53 antibody comprised in the sample.
-
公开(公告)号：US20220252592A1
公开(公告)日：2022-08-11
申请号：US17730403
申请日：2022-04-27
Applicant: Roche Diagnostics Operations, Inc.
Inventor： Herbert Andres , Johann Karl , Ursula Kunert , David Morgenstern , Nina Meissler , Marion Niessner , Magdalena Swiatek-de Lange
IPC: G01N33/564 , G01N33/574 , C07K16/46
Abstract: The disclosure relates to an in vitro method for detecting an antibody to p53 (anti-p53 antibody) in a sample, the method comprising: incubating a sample to be analyzed with a p53 capture antigen and a p53 detection antigen, whereby a complex comprising the p53 capture antigen, the anti-p53 antibody and the p53 detection antigen is formed, separating the complex formed from unbound detection antigen and measuring the complex obtained via the detection antigen comprised therein, thereby detecting the anti-p53 antibody comprised in the sample.
-
Patent Agency Ranking
公开(公告)号：US10301383B2
公开(公告)日：2019-05-28
申请号：US15003988
申请日：2016-01-22
Applicant: Roche Diagnostics Operations, Inc.
Inventor： Herbert Andres , Hartmut Duefel , Michael Gerg , Frank Kowalewsky , Christian Scholz , Michael Schraemi
IPC: C07K16/00 , C07K16/22 , C12N9/90 , C07K16/12 , G01N33/74 , C07K16/40 , G01N33/573 , C07K14/475 , C07K14/65
Abstract: Isolated antibodies that specifically bind to an epitope comprised in the stretch of amino acids ranging from amino acid 76 to amino acid 84 of human insulin-like growth factor-1 precursor (SEQ ID NO:1). Use of the novel antibodies for the sensitive and specific detection of insulin-like growth factor-1, in some embodiments while in the presence of high excess concentration of insulin-like growth factor-2, for example in a bodily fluid sample.
-
公开(公告)号：US20170115294A1
公开(公告)日：2017-04-27
申请号：US15399801
申请日：2017-01-06
Applicant: Roche Diagnostics Operations, Inc.
Inventor： Norbert Wild , Ursula Garczarek , Andrea Geistanger , Herbert Andres , Marie-Luise Hagmann , Johann Karl , Freidemann Krause , Michael Pfeffer , Wolfgang Rollinger , Michael Tacke , Michael Thierolf
IPC: G01N33/574
CPC classification number: G01N33/57419 , C12Q1/6886 , G01N2333/4727 , G01N2333/805 , G01N2333/8146 , G01N2333/9121
Abstract: The present invention relates to the diagnosis of colorectal cancer. It discloses the use of protein S100A12 in the diagnosis of colorectal cancer. It relates to a method for diagnosis of colorectal cancer from a stool sample, derived from an individual by measuring S100A12 in said sample. Measurement of S100A12 can, e.g., be used in the early detection or diagnosis of colorectal cancer.
-
公开(公告)号：US20140120561A1
公开(公告)日：2014-05-01
申请号：US14069445
申请日：2013-11-01
Applicant: Roche Diagnostics Operations, Inc.
Inventor： Herbert Andres , Hartmut Duefel , Michael Gerg , Frank Kowalewsky , Christian Scholz , Michael Schraeml
CPC classification number: C07K16/22 , C07K14/475 , C07K14/65 , C07K16/1203 , C07K16/40 , C07K2317/34 , C07K2317/565 , C07K2317/92 , C07K2319/00 , C07K2319/21 , C07K2319/22 , C07K2319/23 , C07K2319/24 , C07K2319/35 , C07K2319/41 , C07K2319/43 , C12N9/90 , C12Y502/01008 , G01N33/573 , G01N33/74 , G01N2333/99
Abstract: Isolated antibodies that specifically bind to an epitope comprised in the stretch of amino acids ranging from amino acid 76 to amino acid 84 of human insulin-like growth factor-1 precursor (SEQ ID NO:1). Use of the novel antibodies for the sensitive and specific detection of insulin-like growth factor-1, in some embodiments while in the presence of high excess concentration of insulin-like growth factor-2, for example in a bodily fluid sample.
Abstract translation: 分离的抗体特异性结合包含在人类胰岛素样生长因子-1前体的氨基酸76至氨基酸84的氨基酸区段中的表位（SEQ ID NO：1）。 在一些实施方案中，当存在高过量浓度的胰岛素样生长因子-2（例如在体液样品中）时，使用新型抗体用于敏感和特异性检测胰岛素样生长因子-1。
-
9.发明授权公开(公告)号：US11644472B2
公开(公告)日：2023-05-09
申请号：US16217612
申请日：2018-12-12
Applicant: Roche Diagnostics Operations, Inc.
Inventor： Herbert Andres , Dirk Block , Johann Karl , Peter Kastner , Ursula-Henrike Wienhues-Thelen , Roberto Latini , Serge Masson , Andre Ziegler , Edelgard Kaiser , Stefan Palme , Markus Thomas , Simona Barlera
CPC classification number: G01N33/6887 , G01N33/6893 , G01N2800/326
Abstract: A method for predicting the risk of recurrence of Atrial Fibrillation in a subject based on measuring the amount of the biomarker Angiopoietin-2 (Ang-2) and optionally of at least one further biomarker in a sample from the subject is described. Also described is a method of diagnosing Atrial Fibrillation in a subject suspected to suffer from Atrial Fibrillation based on measuring the amount of the biomarker Angiopoietin-2 (Ang-2) and optionally of at least one further biomarker in a sample from the subject. Also described are devices adapted to carry out the method of the present disclosure.
-
公开(公告)号：US11125695B2
公开(公告)日：2021-09-21
申请号：US16111646
申请日：2018-08-24
Applicant: Roche Diagnostics Operations, Inc.
Inventor： Hans-Peter Josel , Herbert Andres , Michaela Windfuhr , Oliver Larbolette , Stefan Quint
IPC: G01N21/76 , G01N21/66 , G01N33/543 , C07F15/00 , G01N27/30
Abstract: The disclosure concerns methods for the detection of an analyte in a sample by electrochemiluminescence using new reagent compositions. New reagent compositions, reagent kits for measuring electrochemiluminscence (ECL) and electrochemiluminescence detection methods using the new reagent compositions are disclosed. In particular, the disclosure relates to the use of novel combinations of compounds which can be used in said measurements to provide improved assay performance.
-
-
-
-
-
-
-
-
-
Search Results
17
records
(took 0.019 seconds)
